Helen Torley, PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC. (HALO), sold 60,000 shares at $107.90 ($6.6M) on 2026-10-06, disclosed to the SEC on 2026-10-08.
Scheduled sale ($6.6M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $107.90 | 2,300 | $248K | 3.8% |
| 2 | $109.33 | 6,000 | $656K | 9.9% |
| 3 | $109.89 | 9,920 | $1.1M | 16.5% |
| 4 | $110.81 | 1,780 | $197K | 3.0% |
| 5 | $111.03 | 8,600 | $955K | 14.4% |
| 6 | $111.84 | 10,300 |
| $1.2M |
| 17.4% |
| 7 | $112.78 | 900 | $102K | 1.5% |
| 8 | $113.69 | 200 | $23K | 0.3% |
| 9 | $108.18 | 4,810 | $520K | 7.9% |
| 10 | $108.91 | 3,090 | $337K | 5.1% |
| 11 | $110.00 | 11,900 | $1.3M | 19.8% |
| 12 | $110.51 | 200 | $22K | 0.3% |
| Total | $110.18 avg | 60,000 | $6.6M | 100% |
| Filing → |
| HALO | SELL | 2026-07-09 | $153K | — | Filing → |
| HALO | SELL | 2026-06-03 | $3.4M | — | Filing → |
| HALO | SELL | 2026-05-13 | $3.4M | — | Filing → |